On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: Are there pharmacodynamic arguments for using higher doses?

Digestion

Volumn 88, Issue 1, 2013, Pages 56-63

  Bruley Des Varannes, Stanislas ^a   Coudsy, Bogdana ^b   Waechter, Sandra ^d   Delemos, Byron ^e   Xiang, Jim ^e   Lococo, John ^e   Ducrotté, Philippe ^c  

^a HÔTEL DIEU   (France)

^b Janssen Cilag   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d Janssen Cilag   (Switzerland)

^e Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Body mass index; Erosive oesophagitis; Gastroesophageal reflux disease; Obesity; Pantoprazole; Pharmacodynamics; Proton pump inhibitors; Rabeprazole

Indexed keywords

PANTOPRAZOLE; RABEPRAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESOPHAGEAL PH MONITORING; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PH; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STOMACH PH; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROTON PUMP INHIBITORS; RABEPRAZOLE; YOUNG ADULT;

EID: 84880266692     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000351389     Document Type: Article

References (37)

1. World Health Organization Fact Sheet #311: Obesity and Overweight. September 2006. Available at: http://www.who.int/mediacen tre/factsheets/fs311/en/index.html (accessed October 19, 2007).
2. Department of Health and Human Services: Centers for Disease Control and Prevention. National Center for Health Statistics. Prevalence of Overweight, Obesity, and Extreme Obesity among Adults: United States, Trends 1960-1962 through 2007-2008. Available at: http://www.cdc.gov/nchs/data/hestat/obesi ty-adult-07-08/obesity-adult-07-08. htm#table1.
3. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publ #98-4083, September 1998. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf (accessed June 5, 2007).
4. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO: Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
6. Corley DA, Kubo A: Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 2619-2628.
7. Nam SY, Choi IJ, Nam BH, Park KW, Kim CG: Obesity and weight gain as risk factors for erosive oesophagitis in men. Aliment Pharmacol Ther 2009; 29: 1042-1052.
8. Hampel H, Abraham N, El-Serag HB: Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
9. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr: Body mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 2340-2348.
10. El-Serag HB, Graham DY, Satia JA, Rabeneck L: Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 1243-1250.
11. Veugelers PJ, Porter GA, Guernsey DL, Casson AG: Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006; 19: 321-328.
12. El-Serag H: The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 2008; 53: 2307-2312.
13. Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ: Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132: 883-889.
14. Boeckxstaens GEE: Review article: the pathophysiology of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2007; 26: 149-160.
15. El-Serag HB, Tran T, Richardson P, Ergun G: Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006; 41: 887-891.
16. Wilson LJ, Ma W, Hirschowitz BI: Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999; 94: 2840-2844.
17. Wu AH, Tseng CC, Bernstein L: Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98: 940-948.
18. Quiroga E, Cuenca-Abente F, Flum D, Dellinger EP, Oelschlager BK: Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance. Surg Endosc 2006; 20: 739-743.
19. Tilg H, Moschen AR: Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. Gastroenterology 2010; 139: 1823-1826.
20. Hirschowitz BI: A critical analysis, with appropriate controls, of gastric and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-1158.
21. McDougall NI, Johnston BT, Collins JS, Mc-Farland RJ, Love AH: Three-to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1016-1022.
22. Talley NJ, Armstrong D, Junghard O, Wiklund I: Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24: 371-376.
23. Sheu BS, Chang WL, Cheng HC, Kao AW, Lu CC: Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole. Am J Gastroenterol 2008; 103: 2209-2214.
24. Crowell MD, Lacy BE, DiBaise JK, Sharma VK: Obesity does not reduce the efficacy of proton pump inhibitors for mediating esophageal acid exposure in patients with reflux symptoms. Gastroenterology 2010; 138(suppl 1):S135.
25. Sheu BS, Cheng HC, Chang WL, Chen WY, Kao AW: The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102: 2387-2394.
26. Hanley MJ, Abernethy DR, Greenblatt DJ: Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
27. Jacobson BC: Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci 2008; 53: 2313-2317.
28. Warrington S, Baisley K, Lee D, et al: Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment Pharmacol Ther 2007; 25: 511-517.
29. Miner P, Delemos B, Xiang J, Lococo J, Ieni J: Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24 h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. Aliment Pharmacol Ther 2010; 31: 991-1000.
30. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(suppl 1):59-67.
31. Bruley des Varannes S, Coron E, Galmiche JP: Short and long-term PPI treatment for GERD. Do we need more potent antisecretory drugs? Best Pract Res Clin Gastroenterol 2010; 24: 905-921.
32. Galmiche JP, Bruley des Varannes S: Gastric pHmetry: clinical relevance; in Scarpignato C, Bianchi Porro G (eds): Clinical Investigation of Gastric Function. Basel, Karger, 1990, pp 32-54.
33. Wisén O, Rössner S, Johansson C: Gastric secretion in massive obesity. Evidence for abnormal response to vagal stimulation. Dig Dis Sci 1987; 32: 968-972.
34. Fisher BL, Pennathur A, Mutnick JL, Little AG: Obesity correlates with gastroesophageal reflux. Dig Dis Sci 1999; 44: 2290-2294.
35. Ortiz V, Ponce M, Fernandez A, Martinez B, Ponce JL, Garrigues V, Ponce J: Value of heartburn for diagnosing gastroesophageal reflux disease in severely obese patients. Obesity 2006; 14: 696-700.
36. Fletcher J, Derakhshan MH, Jones GR, Wirz AA, McColl KE: BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut 2011; 60: 442-448.
37. Heading RC, Mönnikes H, Tholen A, Schmitt H: Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011; 11: 52.